4 views left Get unlimited views with a free account

Take your business to the next level. Explore the latest trends and actionable insights to inform business strategy and pinpoint opportunities and risks.

Number of ongoing Clinical Trials (for drugs) involving Polycystic Ovarian Syndrome by Phase

Industry: Pharmaceuticals
Current: Other Industry Indicators

There are currently 254 ongoing clinical trials involving Polycystic Ovarian Syndrome
Of the 254 trials,96 trials are in Phase II
Furthermore, 47 trials are in Phase IV

Number of ongoing Clinical Trials (for drugs) involving Polycystic Ovarian Syndrome by Phase

View as table

The global pharmaceutical industry is steadily developing new drugs for Polycystic Ovarian Syndrome, a Women's Health condition. The largest number of ongoing clinical trials for Polycystic Ovarian Syndrome is conducted in the Asia-Pacific region. North America and Middle East and Africa are among some of the other prominent regions engaged in Polycystic Ovarian Syndrome-related drug trials.

University of Virginia: The leading ongoing Polycystic Ovarian Syndrome related clinical trial sponsor

University of Virginia is the top sponsor for Polycystic Ovarian Syndrome-related ongoing clinical trials.

Shanghai People's Hospital 9, Shanghai Jiao Tong University School of Medicine, Royan Institute and Isfahan University of Medical Sciences are among other notable clinical trial sponsors involved in Polycystic Ovarian Syndrome. A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Polycystic Ovarian Syndrome

Metformin hydrochloride (Glucophage/ Metgluco/ Glifage/ Dianben/ Diabex/ Getemin/ Glucovance/ Dabex / Stagid), Follitropin alfa (Gonal F / Ovidrel) and Follitropin beta (Follistim / Puregon / Follistim AQ) are among the key marketed drugs involving Polycystic Ovarian Syndrome.

Metformin hydrochloride is a biguanide derivative, acts as anti-diabetic or anti-hyperglycemic agent. It functions via Adenosine Monophosphate Activated Protein Kinase Activator mechanism of action. Metformin hydrochloride is formulated as film coated tablets and powder for solution for oral route of administration. Metformin hydrochloride was first approved in 1960 and is marketed globally the US, UK, China, Japan, Germany, and France by several prominent pharma giants including EMD Serono Inc.

Follitropin alfa (Gonal F / Ovidrel) is a recombinant human follicle-stimulating hormone (r-hFSH) produced in Chinese Hamster Ovary (CHO) cells by recombinant DNA technology. It functions via Follicle Stimulating Hormone Receptor (Follitropin Receptor or FSHR) Agonist mechanism of action. Follitropin alfa is formulated in the form of injection solution and injection lyophilized powder solution, prefilled syringes for subcutaneous route and intramuscular route of administration. Follitropin alfa was first approved in 1995 and is marketed globally in the US, UK, China, Japan, Germany, and France by several prominent pharma giants including EMD Serono Inc.